Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes

Clinical Therapeutics

Volumn 38, Issue 10, 2016, Pages 2265-2276

  Heise, Tim ^a   Jordan, Jens ^b   Wanner, Christoph ^c   Heer, Martina ^a   Macha, Sreeraj ^d   Mattheus, Michaela ^e   Lund, Søren S ^e   Woerle, Hans J ^e   Broedl, Uli C ^e  

^a Profil Institut fur Stoffwechselforschung GmbH   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d MERCK RESEARCH LABORATORIES   (United States)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

electrolytes; natriuresis; pharmacodynamics

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; BICARBONATE; CHLORIDE; EMPAGLIFLOZIN; GLUCOSE; METFORMIN; RENIN; SODIUM; UREA; URIC ACID; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ALKALOSIS; ARTICLE; BICARBONATE BLOOD LEVEL; BLOOD PH; CAPILLARY BLOOD; CHLORIDE BLOOD LEVEL; CHLORIDE URINE LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; FAINTNESS; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HEART RATE; HUMAN; MALE; MULTIPLE DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PHARMACODYNAMICS; PLASMA RENIN ACTIVITY; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SERUM OSMOLALITY; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL; URINARY FREQUENCY; URINE OSMOLALITY; URINE PH; URINE VOLUME; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; DRUG EFFECTS; MIDDLE AGED;

ADULT; AGED; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BODY WEIGHT; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; RENIN-ANGIOTENSIN SYSTEM; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84994268329     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.09.001     Document Type: Article

References (26)

1. 1 Grempler, R., Thomas, L., Eckhardt, M., et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14 (2012), 83–90.
2. 2 Gerich, J.E., Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 27 (2010), 136–142.
3. 3 List, J.F., Woo, V., Morales, E., et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32 (2009), 650–657.
4. 4 Ferrannini, E., Solini, A., SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 8 (2012), 495–502.
5. 5 Häring, H.-U., Merker, L., Seewaldt-Becker, E., et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 37 (2014), 1650–1659.
6. 6 Häring, H.-U., Merker, L., Seewaldt-Becker, E., et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial. Diabetes Care 36 (2013), 3396–3404.
7. 7 Kovacs, C.S., Seshiah, V., Swallow, R., et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 16 (2013), 147–158.
8. 8 Roden, M., Weng, J., Eilbracht, J., et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 1 (2013), 208–219.
9. 9 DeFronzo, R.A., Davidson, J.A., Del, P.S., The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 14 (2012), 5–14.
10. 10 Baker, W.L., Smyth, L.R., Riche, D.M., et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 8 (2014), 262–275.
11. 11 Chilton, R., Tikkanen, I., Cannon, C.P., et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 17 (2015), 1180–1193.
12. 12 Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circ 129 (2014), 587–597.
13. 13 Muller, M.J., Bosy-Westphal, A., Klaus, S., et al. World Health Organization equations have shortcomings for predicting resting energy expenditure in persons from a modern, affluent population: generation of a new reference standard from a retrospective analysis of a German database of resting energy expenditure. Am J Clin Nutr 80 (2004), 1379–1390.
14. 14 Heise, T., Mattheus, M., Woerle, H.J., et al. Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study. Clin Ther 37 (2015), 793–803.
15. 15 Barnett, A.H., Mithal, A., Manassie, J., et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2 (2014), 369–384.
16. 16 Ridderstrale, M., Andersen, K.R., Zeller, C., et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2 (2014), 691–700.
17. 17 Rosenstock, J., Jelaska, A., Frappin, G., et al. Improved glucose control with weight loss, lower insulin doses and no increased hypoglycemia with empagliflozin added-on to titrated multiple daily injections of insulin in obese inadequately controlled patients with type 2 diabetes. Diabetes Care 37 (2014), 1815–1823.
18. 18 Tikkanen, I., Narko, K., Zeller, C., et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 33 (2014), 420–428.
19. 19 Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
20. 20 Skrtic, M., Yang, G.K., Perkins, B.A., et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetol 57 (2014), 2599–2602.
21. 21 Lytvyn, Y., Škrtić, M., Yang, G.K., et al. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol 308 (2015), F77–83.
22. 22 Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 2014;35:391–404.
23. 23 Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
24. 24 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 3:Suppl (2013), 1–150.
25. 25 Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 37 (2016), 2129–2200.
26. 26 Ferrannini, G., Hach, T., Crowe, S., et al. Energy balance following sodium-glucose co-transporter-2 inhibition. Diabetes Care 38 (2015), 1730–1735.